Illumina Files Patent Infringement Suit against Genoma SA
News Apr 22, 2016
Illumina, Inc. has announced that it, and its wholly owned subsidiary, Verinata Health, Inc. (together "Illumina"), filed a patent infringement suit against Genoma SA in the Federal Patent Court in Switzerland. Illumina is seeking all available remedies, including damages and injunctive relief. The patents asserted are European Patent (CH) 2 183 693 B1, European Patent (CH) 0 994 963 B2, European Patent (CH) 1 981 995 B1, and European Patent (CH) 2 514 842.
The patents are directed to using cell-free fetal DNA for non-invasive prenatal testing (NIPT). The suit accuses Genoma's Tranquility® NIPT testing service, including its use of next-generation sequencing to analyze cell-free DNA from a sample of maternal blood. Genoma's testing facility in Switzerland also services samples collected from its other labs, including those located in Spain and Italy.
"We will continue to monitor activities in the NIPT field and file suits where appropriate to protect our substantial investments in this technology covered by our intellectual property," said Charles Dadswell, Senior Vice President and General Counsel for Illumina. The Tranquility NIPT service uses the IONA® Test sold by Premaitha Health plc. Illumina previously filed separate suits against Premaitha in the United Kingdom for sale of the IONA Test.
Scientists at McGill have found the answer to a question that perplexed Charles Darwin; if natural selection works at the level of the individual, fighting for survival and reproduction, how can a single colony produce worker ants that are so dramatically different in size – from “minor” workers to large-headed soldiers with huge mandibles – especially if they are sterile?
Scientists have developed a successful method to make truly personalized predictions of future disease outcomes for patients with certain types of chronic blood cancers. The study combined extensive genetic and clinical information to predict the prognosis for patients with myeloproliferative neoplasms.
For centuries, gardeners have attempted to breed blue roses with no success. But now, thanks to modern biotechnology, the elusive blue rose may finally be attainable. Researchers have found a way to express pigment-producing enzymes from bacteria in the petals of a white rose, tinting the flowers blue.
2nd International Conference on Computational Biology and Bioinformatics
May 17 - May 18, 2019
2nd World Congress on Genetics & Genetic Disorders
May 13 - May 14, 2019